PSC
CBIO

Prentiss Smith & Co’s Crescent Biopharma CBIO Stock Holding History

Prentiss Smith & Co’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-151
Closed -$45.8K – 65
2022
Q4 		$45.8K Buy
151
+11
+8% +$1.62K 0.04% 61
2022
Q3 		$8K Hold
140
– – 0.01% 62
2022
Q2 		$8K Hold
140
– – 0.01% 68
2022
Q1 		$16K Hold
140
– – 0.01% 73
2021
Q4 		$20K Hold
140
– – 0.01% 79
2021
Q3 		$31K Hold
140
– – 0.02% 75
2021
Q2 		$32K Hold
140
– – 0.02% 76
2021
Q1 		$42K Hold
140
– – 0.02% 74
2020
Q4 		$53K Buy
+140
New +$49.1K 0.03% 76
2019
Q4 		– Sell
-170
Closed -$73K – 64
2019
Q3 		$73K Buy
+170
New +$109K 0.05% 60
2019
Q1 		– Sell
-100
Closed -$95K – 61
2018
Q4 		$95K Buy
100
+30
+43% +$36.1K 0.06% 62
2018
Q3 		$101K Hold
70
– – 0.06% 85
2018
Q2 		$113K Hold
70
– – 0.07% 81
2018
Q1 		$114K Hold
70
– – 0.06% 87
2017
Q4 		$118K Sell
70
-30
-30% -$39.7K 0.06% 90
2017
Q3 		$140K Hold
100
– – 0.08% 73
2017
Q2 		$112K Buy
100
+30
+43% +$24.8K 0.06% 85
2017
Q1 		$38K Hold
70
– – 0.02% 130
2016
Q4 		$43K Hold
70
– – 0.03% 126
2016
Q3 		$50K Sell
70
-30
-30% -$23K 0.03% 120
2016
Q2 		$73K Hold
100
– – 0.04% 105
2016
Q1 		$60K Hold
100
– – 0.03% 113
2015
Q4 		$57K Hold
100
– – 0.03% 119
2015
Q3 		$56K Hold
100
– – 0.03% 112
2015
Q2 		$80K Hold
100
– – 0.04% 105
2015
Q1 		$83K Hold
100
– – 0.04% 102
2014
Q4 		$72K Buy
100
+50
+100% +$39.1K 0.03% 117
2014
Q3 		$35K Buy
+50
New +$40.4K 0.02% 124

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Prentiss Smith & Co's CBIO Position: Q1 2023 in Review

Prentiss Smith & Co sold out of Crescent Biopharma (CBIO) in Q1 2023, closing a stake of 151 shares — an estimated $45.8K sold.

Prentiss Smith & Co first reported a position in CBIO in Q3 2014 and held it in 28 quarters. The position peaked at $140K in Q3 2017. 54 funds tracked by Wall St. Rank hold CBIO as of Q1 2023.

  • Prentiss Smith & Co reported no remaining Crescent Biopharma position as of Q1 2023 after selling out during the quarter.
  • Prentiss Smith & Co sold 151 Crescent Biopharma shares in Q1 2023, an estimated $45.8K.
  • Prentiss Smith & Co first reported a position in Crescent Biopharma in Q3 2014 and held it in 28 quarters.
  • Prentiss Smith & Co's Crescent Biopharma position peaked at $140K in Q3 2017.
  • 54 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2023.

Based on Prentiss Smith & Co's 13F filing for Q1 2023, filed 28 Apr 2023.